Milestone Pharmaceuticals’ CARDAMYST: A Game Changer in PSVT Treatment with Significant Market Potential
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research ...
Viatris Inc. (VTRS): David Einhorn’s Top Stock Pick
We recently compiled a list of the David Einhorn’s Stock Portfolio: Top 10 Stocks to Buy. In this article, we are going to ...
World Thrombosis Day raises global awareness of blood clot dangers through actionable initiatives
Today is World Thrombosis Day, a global campaign established by the International Society on Thrombosis and Haemostasis (ISTH) to engage ...
Viatris Inc. (VTRS): A Strategic Shift in Healthcare Investments
We recently published a list of 8 Stocks Under $20 To Invest In Now. In this article, we are going to take a look at where ...
Vertex Pharmaceuticals (VRTX) Receives a Hold from Morgan Stanley
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price ...
CSR Wire4d
Viatris 2023 Sustainability Report: Reducing Packaging Material
We are continuously looking for ways to reduce the volume and types of materials being used in packaging while safeguarding access to high-quality medicines and maintaining compliance with various ...
bovnews6d
Jefferies Issues Buy Rating for Viatris Inc (VTRS) Stock
On Tuesday, Viatris Inc (VTRS) stock saw a decline, ending the day at $11.32 which represents a decrease of $-0.01 or -0.09% from the prior close of $11.33. The stock opened at $11.33 and touched a ...